Women are more prone to the condition than men, and Black and Latinx people tend to have more persistent and severe symptoms ...

Delgocitinib cream is more effective and has a better safety profile than oral alitretinoin for the treatment of severe chronic hand eczema.

The findings were published online in The Lancet on April 16, 2025.

Chronic hand eczema (CHE) is a multifactorial condition with significant physical, psychological, and socioeconomic burdens. Its complex pathogenesis often does not align with clinical presentation, ...

Treatment options for severe chronic hand eczema are limited and carry troublesome adverse effects. Delgocitinib cream had superior efficacy compared with oral alitretinoin for this patient ...

These announcements underscore LEO Pharma's continued leadership in dermatological care and represent a significant step forward in improving treatment options for chronic hand eczema patients.

CNA's Kora Fong has struggled with eczema for more than 10 years, but in January, her condition took a turn for the worse.

Hyperpigmented patches and lichenification in visible areas like the face, neck, and hands can trigger social ... to years following successful eczema treatment, creating a visible reminder ...

"We are proud to contribute to the overall understanding of moderate to severe chronic hand eczema, helping uncover potentially new treatment options for those living with skin conditions like CHE." ...

Germany has become the debut market for LEO Pharma's Anzupgo, the first topical treatment specifically approved for chronic hand eczema (CHE). The launch of pan-JAK inhibitor Anzupgo (delgocitinib ...

Delgocitinib cream had superior efficacy and a better safety profile compared with oral alitretinoin for the treatment of severe chronic hand eczema, the randomized phase III DELTA FORCE trial showed.